Form 4: Syndax Director Aleksandra Rizo Awarded 24,000 RSUs
Insider Transaction Report
Syndax Pharmaceuticals Director Aleksandra Rizo received an award of 24,000 Restricted Stock Units, vesting in one year.
Summary
- Aleksandra Rizo, a Director of Syndax Pharmaceuticals Inc. (SNDX), was awarded 24,000 shares of Common Stock.
- The transaction occurred on February 4, 2026.
- These shares are Restricted Stock Units (RSUs) granted at a price of $0.
- The RSUs will vest one year from the grant date.
- The shares underlying the RSUs are not deliverable, transferable, or salable until the earlier of separation from service, death, disability, or a change in control.
- Following this transaction, Aleksandra Rizo beneficially owns a total of 49,000 shares of Common Stock.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive for corporate governance, as the RSU award aligns the director's long-term interests with shareholder value, though it's a routine compensation event.
Positives
- Director Aleksandra Rizo received an award of 24,000 Restricted Stock Units, aligning her interests with long-term shareholder value.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that equity awards like Restricted Stock Units are a common form of director compensation in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term commitment and align leadership interests with shareholder returns.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Application | The award of Restricted Stock Units to Director Aleksandra Rizo is consistent with the company's existing compensation policies for non-employee directors. | 02/04/2026 | Reinforces alignment between director incentives and long-term shareholder value. |
Stakeholder Impact
- Shareholders: Increased alignment of director's interests with long-term company performance due to equity-based compensation.
- Director: Receives future equity compensation tied to company performance and continued service.
Next Steps
- The awarded Restricted Stock Units will vest one year from the grant date (February 4, 2026).
- Shares will be delivered upon the earlier of separation from service, death, disability, or a change in control.
Key Dates
| Date | Description |
|---|---|
| 02/04/2026 | Date of RSU award transaction. |
| 02/06/2026 | Signature date of the filing by attorney-in-fact. |
Keywords
Syndax Pharmaceuticals, SNDX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.